This platform offers an exciting solution to overcoming the renowned difficulty in the formulation of PTX, as well as allowing for combination therapy with cytochrome C. Further formulation optimization is needed in order to fully exploit the synergistic efficacy observed in vitro and, ultimately, in vivo translation will elucidate the further potential of this platform as a feasible treatment for liver cancer. Here, CYCS is linked to liver cancer.